Iron sucrose API, assigned CAS 8047-67-4, is a polynuclear iron(III)-hydroxide core stabilized by sucrose, with a weight-average molecular weight range of 34,000–60,000 Da and a specified iron content of 5.0–5.6% w/w as Fe(III). The amorphous dark brown powder is freely soluble in water and practically insoluble in ethanol, yielding a 10% w/v aqueous solution with a pH of 10.5–11.0. The sucrose constituent, specified at 30.0–33.0% w/w, provides steric stabilization of the colloidal iron core and confers the thermodynamic stability required for parenteral administration. Model designations for this API typically distinguish the manufacturing stage—raw precipitated iron sucrose, spray-dried, and lyophilized—and the microbial quality grade; injectable-grade material is produced as a sterile, non-pyrogenic intermediate for finished injection manufacture, while non-sterile API is supplied for compounding into tablet, capsule, and granule dosage forms. The particle-size distribution of the spray-dried grade is controlled by analytical sieving per USP <811>, and residual moisture is maintained by Karl Fischer titration to limit hydrolysis of the sucrose ligand during storage.

The therapeutic classification of iron sucrose is a parenteral iron replacement agent for iron deficiency anemia, with the injectable formulation indicated in chronic kidney disease and other conditions where oral iron is either insufficient or poorly tolerated. Use of the API in oral solid dosage forms is technically possible but pharmacokinetically constrained: the 34,000–60,000 Da complex does not dissociate efficiently at gastric pH, and the Fe(III) core remains bound to sucrose during intestinal transit, yielding fractional absorption markedly lower than ferrous sulfate heptahydrate in standard bioavailability testing. Consequently, the oral and injectable grades of this API are not interchangeable, and the specification set diverges at the level of endotoxin burden, bioburden, and particulate matter.

What Differentiates Iron Sucrose from Iron Dextran, Sodium Ferric Gluconate, and Ferric Carboxymaltose in Clinical Use?

The molecular weight of the intact complex governs both the rate of reticuloendothelial clearance and the extent of labile iron release into plasma. Iron sucrose occupies an intermediate position between the higher-molecular-weight dextran and carboxymaltose complexes and the smaller, more labile gluconate complex. The reported plasma half-life of the intact iron sucrose complex is approximately 5.9 h, with an apparent volume of distribution of approximately 8 L and a total body clearance of 1.2 L/h. Uptake occurs primarily in the reticuloendothelial system of the liver, spleen, and bone marrow, where the iron is transferred to transferrin and incorporated into hemoglobin. This kinetic profile permits repeated dosing in hemodialysis patients but precludes total-dose infusion because the transient saturation of transferrin following larger single doses increases the measurable labile plasma iron fraction.

The higher labile iron fraction of sodium ferric gluconate has been associated with transient hypotensive episodes during rapid infusion, whereas the dextran compounds carry a well-documented risk of dextran-induced anaphylactoid reactions that historically mandated a test dose. Iron sucrose avoids dextran-related immunogenicity while maintaining a sufficiently stable complex to limit free iron release below the threshold associated with acute oxidative stress. Ferric carboxymaltose, with a nominal iron content of 28% w/w and an allowance of 750–1,000 mg per infusion, permits fewer clinic visits for iron repletion but requires careful dilution and slower infusion rates to minimize hypophosphatemia arising from fibroblast growth factor-23-mediated phosphate wasting.

Within the framework of Ph. Eur. and USP monographs, the specification profile for iron sucrose API encompasses identity, assay, pH, sucrose content, free iron, heavy metals, residual solvents, water content, and, for injectable grade, bacterial endotoxins. Assay of iron is performed by complexometric titration with disodium edetate after acid hydrolysis, with the acceptance range fixed at 5.0–5.6% w/w. Sucrose is quantified by high-performance liquid chromatography with refractive index detection, and the specification range of 30.0–33.0% w/w must be met to maintain the stoichiometric ratio of the complex. The pH of a 10% w/v solution is controlled between 10.5 and 11.0 per USP <791>; this strongly alkaline condition is intrinsic to the stability of the iron(III)-hydroxide core and dictates the use of Type I borosilicate glass or 316L stainless steel for all product-contact surfaces. Bacterial endotoxins are limited to < 5 EU/mg of elemental iron for the injectable finished product per USP <85>, and the final injection must additionally conform to particulate matter limits of ≤ 25 particles per mL at ≥ 10 µm and ≤ 3 particles per mL at ≥ 25 µm per USP <788>. Elemental impurities are controlled per ICH Q3D and USP <232>/<233>, with parenteral limits applied to the injectable grade and oral limits to the non-sterile grade.

The free iron fraction, which represents uncomplexed ferric species capable of immediate redox cycling in aqueous solution, is commonly specified at ≤ 0.05% w/w for the injectable grade. Published pharmacopoeial monographs describe the acceptance criterion in terms of the labeled iron content and permit only trace levels of ionic iron detectable by thiocyanate complexation. Residual solvents are governed by USP <467>, with class-specific limits applicable to the solvents used during precipitation and spray-drying. Water content, determined by Karl Fischer titration, is maintained at < 5.0% w/w to suppress hydrolysis of the sucrose ligand and agglomeration of the amorphous particles during storage.

Thermal Degradation and Moisture Sensitivity in Solid Oral Dosage Form Processing

Differential scanning calorimetry of iron sucrose reveals an amorphous profile with a broad dehydration endotherm and no distinct crystalline melting point; published quantitative glass transition values for this specific complex are limited. The sucrose ligand is subject to caramelization above 160°C at neutral pH, and therefore drying processes must maintain product temperature below this threshold. Spray-drying of the API controls inlet and outlet temperatures within narrow ranges to limit moisture while avoiding sucrose degradation; equipment surfaces are jacketed to prevent localized hot-spot formation that would discolor the powder and alter the molar iron-to-sucrose ratio.

Preparation of tablet, capsule, and granule dosage forms from this API is constrained by the amorphous, hygroscopic character of the powder. Direct compression is impeded by cohesive forces that produce high angle-of-repose values and poor flow through rotary tablet press feed frames; the addition of colloidal silicon dioxide at 0.5–1.0% w/w and microcrystalline cellulose as a compression aid is required to achieve acceptable weight uniformity on production-scale equipment. Wet granulation with aqueous binders introduces localized dissolution of sucrose at the particle surface, resulting in granule hardening and extended tablet disintegration times during scale-up. Use of ethanol or isopropanol as the granulating liquid mitigates this effect but requires explosion-proof fluid-bed dryers and solvent recovery systems. Roller compaction followed by dry granulation avoids the aqueous instability of the sucrose shell but applies mechanical stress that can fracture the amorphous particles and release free iron; compaction force settings must be validated against the free iron specification of the milled granulation.

Pre-drying of the API is required when ambient relative humidity exceeds 60%, because moisture uptake accelerates sucrose dissolution at particle contacts and causes caking in storage bins and feed hoppers. Hygroscopicity under ICH condition 25°C/60% RH and accelerated condition 40°C/75% RH is controlled by double polyethylene liner packaging with desiccant. Dissolution testing of oral solid dosage forms containing iron sucrose via USP <711> Apparatus II at 50 rpm in 0.1 N HCl is complicated by the colloidal, non-ionic nature of the complex; published compendial dissolution standards for iron sucrose tablets do not exist, and method development for these oral products is bespoke to each formulation.

During fill-finish operations on a sterile manufacturing line, the dissolved iron sucrose intermediate is filtered through 0.22 µm polyethersulfone membrane cartridges and filled under nitrogen overlay to minimize oxidation of trace ferrous ion. Terminal sterilization by autoclaving is not applicable because exposure to 121°C for 15 min induces aggregation and precipitation of the sucrose-iron core; therefore, sterile filtration into pre-sterilized Type I borosilicate vials under Grade A conditions is the standard manufacturing route. The finished injection at the labeled concentration of 20 mg Fe/mL has an osmolality of approximately 1,250 mOsm/kg, necessitating dilution into 0.9% sodium chloride infusion bags prior to administration. The recommended dilution limit is 1 mg Fe/mL to reduce the incidence of infusion-site phlebitis and transient blood pressure changes.

Clinical dosing of the injectable product in chronic kidney disease uses 100 mg of elemental iron per hemodialysis session for 10 consecutive sessions; an alternative regimen administers 300 mg as a single infusion over 15–30 min. Total-dose infusion of iron sucrose is not recommended because the transferrin binding capacity is exceeded at higher doses, releasing measurable labile plasma iron that can catalyze Fenton chemistry and transient oxidative stress. Batch-to-batch variability in molecular weight distribution is monitored by gel permeation chromatography with refractive index detection; acceptance limits for polydispersity are established by each manufacturer against a validated reference standard because public pharmacopoeial monographs do not specify a numeric polydispersity index.

When Aqueous Solubility Requirements Exceed the Limits of Oral Iron Salts, Injection-Grade Iron Sucrose Becomes the Controlling Specification

Injection-grade iron sucrose is distinguished from oral-grade material not solely by sterility but by the convergence of endotoxin, particulate, and ionic impurity controls that are unnecessary or less stringent for non-sterile compounding. The injectable grade must meet the bacterial endotoxin limit of < 5 EU/mg Fe, whereas oral grades are typically not tested for endotoxin because the gastrointestinal barrier prevents systemic exposure. Injectables are subjected to visible and subvisible particle inspection following USP <788>, while oral grades are governed by microbial enumeration limits under USP <61>/<62> and the recommendations of USP <1111>, with total aerobic microbial counts not exceeding 10³ CFU/g and combined molds and yeasts not exceeding 10² CFU/g.

The strongly alkaline pH of the dissolved injectable intermediate imposes a corrosion-control specification on manufacturing equipment; aluminum and untreated mild steel are unsuitable because of dissolution and subsequent metal contamination of the product. Borosilicate glass vessels or 316L stainless steel with electropolished product-contact surfaces are standard, and elastomeric closures must be silicone-coated bromobutyl rubber to withstand the alkaline fill solution without extractable-leachable shifts. The oral grade, by contrast, can be processed in conventional stainless steel or glass-lined equipment because the dry powder does not generate the alkaline condition until dissolution, and the non-sterile specification does not require the same level of extractables control.

Because the amorphous iron(III)-hydroxide core is hygroscopic, storage of the API in tightly closed containers at 15–25°C with protection from light and moisture is mandatory; opened containers should be reconditioned with desiccant and used within a validated hold time. Avoid combination of the injectable product with phosphate-containing infusion solutions, because precipitation of iron phosphate occurs under neutral to alkaline conditions; the product must not be mixed with other medications in the same infusion line, and the line should be flushed with 0.9% sodium chloride before and after administration. The API and its aqueous solutions are incompatible with strong reducing agents that can convert Fe(III) to Fe(II) in acidic media, with strong oxidizing agents, and with chelating agents that compete with the sucrose ligand for the iron center. In oral compounding, combination with ascorbic acid at high molar ratios is discouraged because enhanced acidic dissolution of the complex releases ionic iron that increases gastrointestinal mucosal irritation. Finally, although iron sucrose does not require a test dose under current regulatory labeling, hypersensitivity reactions can occur, and facilities for cardiopulmonary resuscitation must be available during parenteral administration; this requirement is documented in the prescribing information of all marketed iron sucrose injections.